TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $170,915 | -37.5% | 19,118 | +7.4% | 0.00% | -50.0% |
| Q2 2023 | $273,362 | -23.1% | 17,797 | +12.6% | 0.00% | -33.3% |
| Q1 2023 | $355,454 | +10.2% | 15,805 | +3.0% | 0.00% | 0.0% |
| Q4 2022 | $322,600 | -10.6% | 15,340 | +4.6% | 0.00% | -25.0% |
| Q3 2022 | $361,000 | +2.3% | 14,671 | +0.8% | 0.00% | +33.3% |
| Q2 2022 | $353,000 | -8.1% | 14,561 | -2.2% | 0.00% | 0.0% |
| Q1 2022 | $384,000 | -16.0% | 14,895 | +1.3% | 0.00% | 0.0% |
| Q4 2021 | $457,000 | +27.3% | 14,708 | -0.8% | 0.00% | 0.0% |
| Q3 2021 | $359,000 | +74.3% | 14,821 | +5.2% | 0.00% | +50.0% |
| Q2 2021 | $206,000 | -45.4% | 14,092 | -6.6% | 0.00% | -33.3% |
| Q1 2021 | $377,000 | +10.2% | 15,091 | +20.3% | 0.00% | 0.0% |
| Q4 2020 | $342,000 | – | 12,548 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |